Others have reported that lapatinib stabilised HER2 levels and its accumulation on the cell surface in breast cancer.50 They report enhanced EGFR/HER2 and HER2/ErbB3 dimer formation with lapatinib but conclude that the dimers will be inactive. This evidence concerns the gene ERBB3 and breast carcinoma.